Table 1:
Participant Demographics
| Low-Risk | High-Risk | Pa | |
|---|---|---|---|
|
| |||
| n | 14 | 16 | |
| Sex = Male (%) | 9(64.3) | 9 (56.2) | 0.72 |
| Age of Biopsy (median [IQR]) | 29.5 [13.3, 57.0] | 16.5 [15.8, 26.8] | 0.38 |
| Age of Onset (median [IQR]) | 20.0 [4.8, 56.3] | 16.0 [15.0, 23.0] | 0.98 |
| Race (%) | 0.49 | ||
| Black/African American | 13 (92.9) | 13 (81.2) | |
| Multi-Racial | 1 (7.1) | 0 (0.0) | |
| White/Caucasian | 0 (0.0) | 1 (6.2) | |
| Unknown | 0 (0.0) | 2 (12.5) | |
| Black (%) | 0.49 | ||
| Yes | 14 (100.0) | 13 (81.2) | |
| No | 0 (0.0) | 2 (12.5) | |
| NA | 0 (0.0) | 1 (6.2) | |
| Genotype-predicted Ancestry (%) | 0.49 | ||
| African | 13 (92.9) | 13 (81.2) | |
| Admixed American | 0 (0.0) | 2 (12.5) | |
| Unknown | 1 (7.1) | 0 (0.0) | |
| NA | 0 (0.0) | 1 (6.2) | |
| Immunosuppression at Biopsy = yes (%) | 5 (35.7) | 4 (25.0) | 0.69 |
| eGFR at Biopsy (median [IQR]) | 66.7 [47.7, 89.4] | 62.9 [45.9, 71.1] | 0.28 |
| UPCR at Biopsy (median [IQR]) | 2.8 [1.4, 5.5] | 2.3 [1.1, 6.1] | 0.90 |
| APOL1 Risk Alleles (%) | <0.01 | ||
| 0 | 3 (21.4) | 0 (0.0) | |
| 1 | 11 (78.6) | 0 (0.0) | |
| 2 | 0 (0.0) | 16 (100.0) | |
| APOL1 Haplotype (%) | <0.01 | ||
| G0_G0 | 3 (21.4) | 0 (0.0) | |
| G0_G1 | 6 (42.9) | 0 (0.0) | |
| G0_G2 | 5 (35.7) | 0 (0.0) | |
| G1_G1 | 0 (0.0) | 5 (31.2) | |
| G1_G2 | 0 (0.0) | 7 (43.8) | |
| G2_G2 | 0 (0.0) | 4 (25.0) | |
a
Continuous variables were tested with non-parametric Wilcoxon rank-sum tests, categorical variables were tested with Exact tests. IQR= interquartile range, eGFR = estimated glomerular filtration rate, UPCR = urine protein/creatinine ratio,